Corline Biomedical AB

OM:CLBIO Rapport sur les actions

Capitalisation boursière : SEK 171.9m

Corline Biomedical Résultats passés

Passé contrôle des critères 0/6

Corline Biomedical has been growing earnings at an average annual rate of 34.5%, while the Pharmaceuticals industry saw earnings growing at 13.1% annually. Revenues have been growing at an average rate of 26.5% per year.

Informations clés

34.5%

Taux de croissance des bénéfices

40.2%

Taux de croissance du BPA

Pharmaceuticals Croissance de l'industrie30.5%
Taux de croissance des recettes26.5%
Rendement des fonds propres-7.4%
Marge nette-22.4%
Prochaine mise à jour des résultats07 Nov 2024

Mises à jour récentes des performances passées

Recent updates

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Aug 24
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

Mar 15
We Think Corline Biomedical (STO:CLBIO) Can Afford To Drive Business Growth

We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Nov 26
We're Interested To See How Corline Biomedical (STO:CLBIO) Uses Its Cash Hoard To Grow

Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

Jun 22
Corline Biomedical (STO:CLBIO) Is In A Strong Position To Grow Its Business

We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Feb 16
We Think Corline Biomedical (STO:CLBIO) Can Easily Afford To Drive Business Growth

Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Jun 14
Companies Like Corline Biomedical (STO:CLBIO) Are In A Position To Invest In Growth

Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Feb 28
Here's Why We're Watching Corline Biomedical's (STO:CLBIO) Cash Burn Situation

Ventilation des recettes et des dépenses

Comment Corline Biomedical gagne et dépense de l'argent. Sur la base des derniers bénéfices déclarés, sur une base LTM.


Historique des gains et des recettes

OM:CLBIO Recettes, dépenses et bénéfices (SEK Millions )
DateRecettesLes revenusDépenses G+ADépenses de R&D
30 Jun 2429-6300
31 Mar 2431-4280
31 Dec 2336-2290
30 Sep 2337-1290
30 Jun 23401270
31 Mar 23384240
31 Dec 22332210
30 Sep 22311190
30 Jun 2223-3170
31 Mar 2219-6170
31 Dec 2117-7160
30 Sep 2115-6150
30 Jun 2113-6150
31 Mar 2114-6160
31 Dec 2015-7180
30 Sep 2014-9180
30 Jun 2014-9180
31 Mar 2014-9170
31 Dec 1912-10170
30 Sep 1911-9160
30 Jun 1911-9150
31 Mar 1910-8150
31 Dec 1810-7130
30 Sep 1817-7160
30 Jun 1816-6170
31 Mar 1815-7170
31 Dec 1716-8190
30 Sep 177-8160
30 Jun 179-8150
31 Mar 1710-6140
31 Dec 169-5140
30 Sep 168-6130
30 Jun 167-6120
31 Mar 165-7110
31 Dec 154-690
31 Dec 144-360
31 Dec 134-270

Des revenus de qualité: CLBIO is currently unprofitable.

Augmentation de la marge bénéficiaire: CLBIO is currently unprofitable.


Analyse des flux de trésorerie disponibles par rapport aux bénéfices


Analyse de la croissance passée des bénéfices

Tendance des revenus: CLBIO is unprofitable, but has reduced losses over the past 5 years at a rate of 34.5% per year.

Accélération de la croissance: Unable to compare CLBIO's earnings growth over the past year to its 5-year average as it is currently unprofitable

Bénéfices par rapport au secteur d'activité: CLBIO is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (4.5%).


Rendement des fonds propres

ROE élevé: CLBIO has a negative Return on Equity (-7.38%), as it is currently unprofitable.


Rendement des actifs


Rendement des capitaux employés


Découvrir des entreprises performantes dans le passé